ArticleThe American journal of pathology1993
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.
Article in The American journal of pathology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 77 citations in OpenAlex.
- Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.Neuro-oncology · 2008Article
- Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.Neuro-oncology · 2007Article
- CHEK2 mutations in primary glioblastomas.Journal of neuro-oncology · 2005Article
- Increased hMSH2 protein expression in glioblastoma multiforme.Journal of neuro-oncology · 2004Article
- What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia.The Malaysian journal of medical sciences : MJMS · 2004Article
- Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.Journal of neuro-oncology · 2000Article
- Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.Journal of neuro-oncology · 2000Article
- Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.Pathology oncology research : POR · 1999Article
- Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas.The American journal of pathology · 1997Article
- In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis.Infection and immunity · 1997Article
- MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.British journal of cancer · 1997Article
- c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization.British journal of cancer · 1996Article
- Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices.Acta neurochirurgica · 1996Article
- Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours.Acta neurochirurgica · 1996Article
- Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.Journal of neurology, neurosurgery, and psychiatry · 1995Article
- p53 protein and epidermal growth factor receptor expression in human astrocytomas.Journal of neuro-oncology · 1995Article
- Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 1995Article
- Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.British journal of cancer · 1994Article
- p53 protein in low-grade astrocytomas: a study with long-term follow-up.British journal of cancer · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of the p53 suppressor gene was evaluated in 102 cases of astrocytic neoplasms. Immunohistochemical staining with a monoclonal antibody (DO-7) and a polyclonal antibody (CM-1) to p53 protein (both wild type and mutant) on formalin-fixed paraffin sections showed a strong correlation with malignancy grade. The staining was positive in 49% of malignant neoplasms (grades III and IV) and in 19 to 29% of grade II astrocytomas, whereas none of the grade I tumors were positive. p53 expression was significantly associated with proliferation rate determined by immunohistochemical proliferating cell nuclear antigen (PCNA)-staining (median PCNA-labeling index (%): 4.22 (DO-7-positive) versus 1.18 (DO-7-negative), P < 0.0001; 4.02 (CM-1-positive) versus 1.18 (CM-1-negative), P < 0.001). Interestingly, in the glioblastoma group (n = 44), p53-positive tumors had higher proliferation indices, suggesting that histologically similar tumors could be divided into prognostically different subgroups by immunohistochemical demonstration of aberrant p53 expression.
Indexed as
Identifiers
7684193PMC1886904W267543562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.